With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
The Early Discovery Chemistry Team at BenevolentAI collaborate with multiple disciplines and functions to enable validation of our AI-derived target predictions and facilitate their entry into our small molecule portfolio. We are looking for an experienced medicinal chemist with excellent communication skills to provide scientific leadership across our growing and diverse pipeline.
The role will involve leadership of chemistry activities on multiple tech deployments in Target ID, including chemogenomics efforts and small molecule project feasibility assessments. Additionally, the role will include leadership of exploratory chemistry projects, such as evaluating novel modalities and therapeutic strategies, and Hit ID of undrugged targets. As part of this work, the role will require close collaboration with biologists, chemoinformaticians and computational chemists, UX/UI designers, software engineers, NLP researchers and ML scientists, to help build the tools required to accelerate the drug discovery process.
The role is located at our London headquarters and is non-lab based.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email firstname.lastname@example.org. Thank you.